Literature DB >> 16978917

Chronic fatigue syndrome.

L D Devanur1, J R Kerr.   

Abstract

Chronic fatigue syndrome (CFS) is thought to have a worldwide prevalence of 0.4-1% with approximately 240,000 patients in the UK. Diagnosis is based on clinical criteria and critically depends on exclusion of other physical and psychiatric diseases. Studies of pathogenesis have revealed immune system abnormalities and chronic immune activation, dysfunction of the hypothalamic-pituitary-adrenal (HPA) axis, brain abnormalities, evidence of emotional stress (comprising host aspects) and evidence of exogenous insults, for example, various microbial infections (Epstein-Barr virus, enteroviruses, parvovirus B19, Coxiella burnetii and Chlamydia pneumoniae), vaccinations and exposure to organophosphate chemicals and other toxins (comprising environmental aspects). Emotional stress appears to be very important as it reduces the ability of the immune system to clear infections, it's presence has been shown to determine whether or not an individual develops symptoms upon virus infection, and it leads to activation of the HPA axis. But, emotional stress is distinct from depression, the presence of which precludes a diagnosis of CFS. There is no specific treatment for CFS other than the much underutilised approach of specific treatment of virus infections. Current priorities are to understand the molecular pathogenesis of disease in terms of human and virus gene expression, to develop a diagnostic test based on protein biomarkers, and to develop specific curative treatments.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16978917     DOI: 10.1016/j.jcv.2006.08.013

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  43 in total

1.  Chronic fatigue syndrome and subsequent risk of cancer among elderly US adults.

Authors:  Cindy M Chang; Joan L Warren; Eric A Engels
Journal:  Cancer       Date:  2012-05-30       Impact factor: 6.860

Review 2.  Nutritional modulation of the intestinal microbiota; future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease.

Authors:  Vincent C Lombardi; Kenny L De Meirleir; Krishnamurthy Subramanian; Sam M Nourani; Ruben K Dagda; Shannon L Delaney; András Palotás
Journal:  J Nutr Biochem       Date:  2018-04-19       Impact factor: 6.048

3.  Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress.

Authors:  Anil Kumar; Beenta Kumari; Puneet Kumar
Journal:  Neurosci Bull       Date:  2010-02       Impact factor: 5.203

4.  Evaluation of prolonged fatigue post-West Nile virus infection and association of fatigue with elevated antiviral and proinflammatory cytokines.

Authors:  Melissa N Garcia; Anne M Hause; Christopher M Walker; Jordan S Orange; Rodrigo Hasbun; Kristy O Murray
Journal:  Viral Immunol       Date:  2014-07-25       Impact factor: 2.257

5.  A nanoelectronics-blood-based diagnostic biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Authors:  R Esfandyarpour; A Kashi; M Nemat-Gorgani; J Wilhelmy; R W Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-29       Impact factor: 11.205

6.  Plasmacytoid dendritic cells in the duodenum of individuals diagnosed with myalgic encephalomyelitis are uniquely immunoreactive to antibodies to human endogenous retroviral proteins.

Authors:  Kenny L De Meirleir; Svetlana F Khaiboullina; Marc Frémont; Jan Hulstaert; Albert A Rizvanov; András Palotás; Vincent C Lombardi
Journal:  In Vivo       Date:  2013 Mar-Apr       Impact factor: 2.155

7.  Chronic fatigue syndrome defies the mind-body-schism of medicine. New perspectives on a multiple realisable developmental systems disorder.

Authors:  Elling Ulvestad
Journal:  Med Health Care Philos       Date:  2008-02-21

8.  Clinical impact of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case series.

Authors:  Øystein Fluge; Olav Mella
Journal:  BMC Neurol       Date:  2009-07-01       Impact factor: 2.474

9.  Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Authors:  Ila R Singh; John E Gorzynski; Daria Drobysheva; Leda Bassit; Raymond F Schinazi
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

10.  Absence of evidence of xenotropic murine leukemia virus-related virus infection in persons with chronic fatigue syndrome and healthy controls in the United States.

Authors:  William M Switzer; Hongwei Jia; Oliver Hohn; HaoQiang Zheng; Shaohua Tang; Anupama Shankar; Norbert Bannert; Graham Simmons; R Michael Hendry; Virginia R Falkenberg; William C Reeves; Walid Heneine
Journal:  Retrovirology       Date:  2010-07-01       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.